University research records
Pontifícia Universidade Católica do Paraná
6 imported, source-linked research records. Open-access records.
Open-access records
Back to university profile →6 matching research records
Topic: Canagliflozin and SGLT2. Only records linked to Pontifícia Universidade Católica do Paraná are included. Historical ingestion is still running; these are imported records, not a count of all research worldwide.
Showing 1–6 of 6 matching records. Counts update as records arrive.
Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we “gliflozin” patients with kidney stone disease?
January 1, 2024 · 4 citations · Open access
Open original record →Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty
July 28, 2023 · 42 citations · Open access
Open original record →CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
March 16, 2023 · 11 citations · Open access
Open original record →A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
April 18, 2021 · 415 citations · Open access
Open original record →The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
August 10, 2020 · 195 citations · Open access
Open original record →Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
January 1, 2019 · 27 citations · Open access
Open original record →